A Multicenter Study on Biomarker Development Utilizing AI Multiomics for Patients with Advanced Solid Malignant Tumors
Not Applicable
- Conditions
- Advanced Solid Malignancies
- Registration Number
- JPRN-UMIN000043899
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2768
Inclusion Criteria
Not provided
Exclusion Criteria
1.Has a history of undergoing allogeneic hematopoietic stem cell transplantation or organ transplantation. 2.Is pregnant. 3.Has a history of another malignant tumor within the three years prior to enrollment. 4.Is judged to be ineligible for enrollment in this research by the study doctor.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method i. Profiles of gene abnormalities, RNA expression, biomarkers, protein expression, etc. in tumor tissue. ii. Profiles of gene abnormalities, RNA expression, biomarkers, etc. in ctNA. iii. Profile of germline gene abnormalities in blood etc. iv. Gut microbiota profile. v. Plasma protein profile.
- Secondary Outcome Measures
Name Time Method i. Profiles of gene abnormalities, RNA expression, biomarkers, protein expression, etc. in tumor tissue And clinical pathological factors, association with clinical course. ii. Relationship between profile of gene abnormality, RNA expression, biomarker, etc. in ctNA and clinical pathological factors, clinical course. iii. Relationship between Germline Gene Abnormality Profiles in Blood etc and Clinicopathological Factors and Clinical Course. iv. Relationship between gut microbiota profile, clinicopathological factors, and clinical course. v. Associations between plasma protein profiles, clinicopathological factors, and clinical course.